Skip to main content

Alto Neuroscience, Inc.

ANRO
Exchange
NYSE
Industry
Pharmaceutical Preparations
SEC CIK
0001999480

In the last 90 days, Alto Neuroscience, Inc. insiders filed 0 open-market purchases and 2 sales; 132 institutions reported holding it in 13F filings for Q3 2026, worth $991.9M in total; no superinvestor holds it.

Key figures

Market capClose on Nov 19, 2026
$1.06B
Insider buysOpen market, last 90 days
0
Insider sellsLast 90 days, $5.64M in total
2
13F holdersQ3 2026, +19 vs. previous quarter
132
13F valueReported value at the end of Q3 2026
$991.9M
Superinvestors holdingAt the end of Q3 2026
0

Price chart

From SEC filings, in USD.

Revenue, FY2025
–
No comparable prior period
Net income, FY2025
-$63.2M
No comparable prior period
Free cash flow, FY2025
-$51.8M
No comparable prior period
Revenue, Q3 FY2026
–
No comparable prior period

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest
5.68M
Shares sold short
Change
+478.5K
+9.2% vs. previous
Days to cover
10.51
At average daily volume

Superinvestors holding ANRO, Q3 2026

Go to the superinvestors tab

No superinvestor reported holding ANRO at the end of Q3 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by Alto Neuroscience, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Nov 18, 2026 (view filing)7:32 PM ETNov 16-182 daysHanley Jr. Michael ConickCHIEF OPERATING OFFICERSSale−75.0K$27.61−$2.07M−100.0%0 after5 lots
Oct 1, 2026 (view filing)9:33 PM ETSep 29-302 daysSmith Nicholas ConradPRESIDENT AND CFOSSale−134.9K$26.45−$3.57M−84.9%24.1K after3 lots
Jul 11, 2024 (view filing)Jul 9-102 daysSavitz AdamCHIEF MEDICAL OFFICERPPurchase+15.0K$12.72+$190.8K+60.4%39.9K after3 lots
Apr 1, 2024 (view filing)Mar 284 daysSmith Nicholas ConradCHIEF FINANCIAL OFFICERPPurchase+6.15K$16.36+$100.6K+29.7%26.9K after2 lots
Feb 8, 2024 (view filing)4:32 PM ETFeb 62 daysAlpha Wave Global, LP and 3 others10% OwnerPPurchase+600.0K$16.00+$9.60M+19.3%3.71M after
Feb 7, 2024 (view filing)Feb 61 daySmith Nicholas ConradCHIEF FINANCIAL OFFICERPPurchase+1.56K$16.00+$25.0KNew position1.56K after
Feb 7, 2024 (view filing)Feb 61 daySavitz AdamCHIEF MEDICAL OFFICERPPurchase+17.0K$16.00+$272.0K+216.5%24.9K after
Feb 7, 2024 (view filing)Feb 61 dayEtkin AmitPRESIDENT AND CEOPPurchase+3.13K$16.00+$50.0K+0.3%1.21M after

Top 10 13F holders, Q3 2026

See all 132 holders

The largest institutional positions in Alto Neuroscience, Inc. at the end of Q3 2026; share changes are against Q2 2026.

Institutions holding ANRO in Q3 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Falcon Edge Capital, LP3,707,757$94.7M2.22%00.0%Unchanged
BlackRock, Inc.2,726,106$69.6M0.00%+605,097+28.5%Added
Commodore Capital LP2,723,196$69.5M5.39%00.0%Unchanged
EcoR1 Capital, LLC2,232,000$57.0M2.80%+2,232,000New
Perceptive Advisors LLC1,760,950$45.0M0.84%+151,057+9.4%Added
Adage Capital Partners GP, L.L.C.1,701,913$43.4M0.06%+101,913+6.4%Added
Vanguard Capital Management LLC1,690,753$43.2M0.00%+301,276+21.7%Added
Spruce Street Capital LP1,676,558$42.8M6.81%+323,511+23.9%Added
Vivo Capital, LLC1,359,915$34.7M3.82%+151,057+12.5%Added
Price T Rowe Associates Inc1,283,867$32.8M0.00%+925,588+258.3%Added

Holders of 5% or more of ANRO

See all 7 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Alto Neuroscience, Inc..

Largest holders of ANRO from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
Perceptive Advisors LLC13G/A9.99%4.18M shares0.00 ppfrom 9.99%Oct 10, 20253 filingsAug 14, 2026SEC
Commodore Capital LP13G/A9.90%3.59M shares0.00 ppfrom 9.90%Oct 27, 20253 filingsMay 15, 2026SEC
Sirenia Capital Management LP13G/A6.20%2.22M shares−1.70 ppfrom 7.90%May 15, 20262 filingsAug 14, 2026SEC
BlackRock, Inc.13G6.00%2.10M shares+3.90 ppfrom 2.10%Oct 21, 20244 filingsJul 27, 2026SEC
Armistice Capital, LLC13G/A6.00%1.62M shares0.00 ppfrom 6.00%Aug 14, 20252 filingsFeb 17, 2026SEC